Yen Nieman, MD
Ophthalmology · Austin, TXNPI 1295825784
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 34.3% of the total.
Across 96 payments — averaging $39.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Rxsight Inc$552
- Alcon$517
- Johnson & Johnson Surgical Vision, Inc.$205
- Biotissue Holdings Inc.$126
- Mallinckrodt Hospital Products Inc.$120
- plus $939 from 16 others
Across 12 payments — averaging $17,917 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$176K
- Kala Pharmaceuticals, Inc.$27K
- Bausch Health US, LLC$12K
What the payments were for
- Food & beverage$3,56495%
- Education$1183%
- Other$642%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $1,286 |
| Rxsight Inc | 4 | $552 |
| Alcon | 7 | $517 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $205 |
| Biotissue Holdings Inc. | 3 | $126 |
| Mallinckrodt Hospital Products Inc. | 2 | $120 |
| Mallinckrodt Enterprises LLC | 1 | $119 |
| Novartis | 2 | $109 |
| Optos, Inc. | 1 | $99 |
| Bausch & Lomb Americas Inc. | 5 | $93 |
| Dompe US, Inc. | 3 | $92 |
| Tarsus Pharmaceuticals, Inc. | 1 | $91 |
| Kowa Research Institute, Inc. | 1 | $87 |
| Carl Zeiss Meditec USA, Inc. | 1 | $64 |
| Sun Pharmaceutical Industries Inc. | 2 | $51 |
| Amgen | 2 | $37 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
| Oyster Point Pharma, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Tearlab Corp | 1 | $15 |
| Thea Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,746 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 265 | $361,404 |
| Cyclosporine | 213 | $148,584 |
| XiidraLifitegrast | 61 | $79,844 |
| Prednisolone Acetate | 243 | $15,288 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $9,832 |
| Loteprednol Etabonate | 36 | $7,335 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $5,256 |
| ValacyclovirValacyclovir Hcl | 93 | $4,707 |
| Alphagan PBrimonidine Tartrate | 11 | $4,389 |
| MoxifloxacinMoxifloxacin Hcl | 69 | $2,337 |
| Fluorometholone | 22 | $2,197 |
| Latanoprost | 169 | $2,048 |
| Difluprednate | 14 | $1,709 |
| Brimonidine Tartrate | 74 | $1,438 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 100 | $1,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Alphagan P | $1,286 | $375,625294 claims |
| Bausch & Lomb Americas Inc.Xiidra | $93 | $79,84461 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $17 | $7,33536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Austin
- Chirag JhaveriAustin$240K
- Sheila BarbarinoAustin$232K
- Aaron RollerAustin$202K
- Philip StoreyAustin$161K
- Robert WongAustin$113K
- Farhan IrshadAustin$111K
- Edward WoodAustin$110K
- Ryan YoungAustin$105K
- Steven DellAustin$94K
- Shelley GhafooriAustin$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.